Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Julie E. Lucero, PhD, MPH and Yvette Roubideaux, MD, MPH
Concepts of “governance,” “trust,” and “culture” can help strengthen research partnerships, honor tribal sovereign authority, counter histories of opportunism, and recognize alternative ways of knowing.
AMA J Ethics. 2020;22(10):E882-887. doi:
10.1001/amajethics.2020.882.
Pamela B. Teaster, PhD, MA, MS and Al O. Giwa, LLB, MD, MBA, MBE
Since ageism contributes to global mental health inequity among older people, responding to their needs should be a clinical, ethical, and policy priority.
AMA J Ethics. 2023;25(10):E765-770. doi:
10.1001/amajethics.2023.765.